For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Nova Ltd. (NVMI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -1 (−100…+100 Quality+Value blend) · Quality 67 · Value -57 · Sentiment 30 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Nova Ltd.
NVMI NASDAQNova Ltd. is a company primarily involved in the development and manufacturing of metrology equipment for the semiconductor industry. Its advanced technological tools are essential for the precise measurement and characterization of materials at various stages of semiconductor fabrication. With a focus on innovation, Nova Ltd. provides integrated solutions that enable chip manufacturers to improve quality, enhance production efficiency, and ensure compliance with industry standards. The company's products serve critical purposes in both research and development as well as high-volume production environments, addressing the growing demand for more complex and smaller semiconductor devices. Headquartered in Israel, Nova Ltd. plays a pivotal role in the global technology market by supporting major semiconductor producers and foundries worldwide. Its emphasis on cutting-edge research and customer-centric solutions underscores its significant contribution to the advancement of semiconductor manufacturing technologies.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
Nova Ltd. is a foreign private issuer — it reports to the U.S. SEC once a year (on Form 20-F or 40-F) rather than filing the quarterly statements (10-Q) that U.S.-domiciled companies must submit. Our financial statements are read directly from SEC filings, so for this company only annual figures exist at the source.
This is a property of how the company files, not missing or broken data — its filing history shows 15 annual reports, the latest filed 2026-02-17, and no quarterly filings . The company may still publish quarterly results on its own investor-relations site.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.90
Total Equity: $1.32B
Shares: 32,800,000
Total Debt: $0.00
Cash: $214.46M
EBITDA: $266.94M
Total Debt: $0.00
Cash: $214.46M
Revenue: $880.58M
Revenue: $880.58M
Revenue: $880.58M
Total Equity: $1.32B
Tax Rate: 14.5%
Equity: $1.32B
Total Debt: $0.00
Cash: $214.46M
Current Liabilities: $224.54M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $1.32B
Shares: 32,800,000
Shares: 32,800,000
CapEx: -$27.70M
Shares: 32,800,000
Stock Price: $418.12
Net Income: $259.22M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 2:26pm (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $416.1M | $570.7M | $517.9M | $672.4M | $880.6M |
| Cost of Revenue | $178.8M | $253.8M | $224.7M | $285.3M | $375.4M |
| Gross Profit | $237.4M | $317.0M | $293.2M | $387.1M | $505.2M |
| Operating Expenses | $125.0M | $167.0M | $160.9M | $199.5M | $251.7M |
| Operating Income | $112.4M | $149.9M | $132.3M | $187.5M | $253.5M |
| Net Income | $93.1M | $140.2M | $136.3M | $183.8M | $259.2M |
| EBITDA | $118.9M | $158.6M | $142.6M | $199.3M | $266.9M |
| EPS | $3.28 | $4.89 | $4.73 | $6.31 | $8.61 |
| EPS (Diluted) | $3.12 | $4.40 | $4.25 | $5.72 | $7.90 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 11:37am (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $126.7M | $111.1M | $107.6M | $157.8M | $214.5M |
| Total Current Assets | $566.5M | $612.9M | $710.2M | $901.9M | $1.4B |
| Total Assets | $805.2M | $984.1M | $1.1B | $1.4B | $2.4B |
| Current Liabilities | $287.9M | $134.1M | $322.8M | $388.2M | $224.5M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $331.4M | $397.1M | $383.1M | $462.6M | $1.0B |
| Total Equity | $473.8M | $587.0M | $750.8M | $927.8M | $1.3B |
| Retained Earnings | $334.7M | $478.1M | $614.4M | $798.1M | $1.1B |
Cash Flow (Annual)
Last updated: Aug 15, 2026 11:37am (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $132.3M | $119.5M | $123.5M | $235.3M | $245.6M |
| Capital Expenditure | -$4.8M | -$21.3M | -$17.2M | -$17.2M | -$27.7M |
| Free Cash Flow | $127.4M | $98.2M | $106.3M | $218.1M | $217.9M |
| Acquisitions (net) | $0 | -$78.5M | $0 | $0 | -$56.4M |
| Net Debt Issued / (Repaid) | — | — | $0 | $0 | $750.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$21.4M | $-112,000 | -$30.0M | -$35.0M |
| Net Change in Cash | -$105.6M | -$15.0M | -$4.1M | $50.2M | $57.0M |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 2:26pm (8d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +37.2% | -9.3% | +29.8% | +31.0% |
| Gross Profit Growth | +33.5% | -7.5% | +32.0% | +30.5% |
| Operating Income Growth | +33.4% | -11.8% | +41.8% | +35.2% |
| Net Income Growth | +50.6% | -2.8% | +34.8% | +41.1% |
| EBITDA Growth | +33.4% | -10.1% | +39.7% | +34.0% |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-15AI-class silicon — gate-all-around, high-aspect 3D NAND, HBM stacks and advanced packaging — adds layers, materials and tighter process windows, and metrology steps scale super-linearly with that complexity, so Nova's dollar content per wafer rises faster than overall fab capex.
Virtual metrology: fabs applying ML to inline process and sensor data to infer dimensions can cut physical sampling rates, so better AI at the customer could shrink tool units per fab even as complexity rises.
Whether AI-driven inference substitutes for or merely schedules physical measurement. Watch measurement-steps-per-wafer disclosures, tool count per new fab, and whether Nova's software/informatics revenue grows faster than hardware.
Sub-nanometer optics and hardware-model calibration, tool-to-tool matching across an installed base, and process-of-record qualification at a handful of leading-edge fabs where a measurement error costs a wafer lot.
AI Lens thesis
AI reaches Nova through three channels of very different sign. Demand: AI compute is the single biggest driver of leading-edge and HBM capacity, and Nova's monetized unit — measurement steps and tools per fab — expands with architectural complexity, which is why it is taking share against a flat industry. Product: optical critical-dimension metrology is an inverse problem solved by physical modeling, so cheaper and stronger ML directly improves accuracy and time-to-recipe, deepening the incumbency of Nova's model libraries rather than commoditizing them — the scarce inputs are the optics, the sensors and the fab-qualified reference data, not the compute. Threat: the same intelligence lets customers predict rather than measure, and lets Chinese and other entrants close the algorithm gap on trailing nodes faster than they could close a physics gap. Net: cheap intelligence enlarges the addressable measurement problem more than it removes the need to physically measure, and Nova owns both the hardware and increasingly the modeling software that captures it.
What the market may be underestimating
Upside Nova's modeling/software layer can monetize virtual metrology itself — selling the prediction engine plus a smaller fleet of reference tools converts a unit-volume threat into higher-margin recurring licence revenue.
Downside Concentration: a handful of leading-edge buyers with strong internal AI teams are the exact customers most able to build hybrid inference-plus-sampling schemes, and they also hold the pricing pen on tool-per-step attach rates.
Outcome range spread 46 · unresolved
Growth Outlook
Analyzed 2026-08-17 16:30The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting with the raw trajectory: revenue went $416M → $571M → $518M → $672M → $881M from 2021-2025, a 30% CAGR but with a visible 2023 cyclical dip (-9% YoY) that reminds you this is still WFE equipment, not SaaS. Net income compounded 38% to $259M, net margin expanded from 22% to 29%, and FCF hit $218M with only $28M capex — capital-light, which is genuinely differentiated versus ASML/LRCX/AMAT. Balance sheet is fortress: zero debt, $214M cash, 6.3x current ratio, $1.32B equity. ROE 19.7%, ROIC 19.6% — high-quality compounder math. At $418 and $13.3B market cap, that's ~51x trailing earnings, ~61x FCF, and ~15x sales on $881M. For a company growing 31% with 29% net margins in a structurally growing metrology niche, 51x isn't obviously insane, but it's priced for continuation, not cyclicality.
The synthesis output is internally incoherent and I'd flag it hard. A "composite fair value" of $219 that gets "signal-adjusted" to $372 and then labeled "fair_value" against $418 is analyst hand-waving — either the DCF says $219 (implying 48% downside) or the signal overlay is doing all the work. The pb_ratio of 0.0104 and ps_ratio of 0.0156 in the canonical metrics are broken (should be ~10x P/B and ~15x P/S) — someone's denominator is in the wrong units. The negative EV/EBITDA and EV/revenue flags are nonsense given $253M positive operating income and $881M revenue; that's a data error, not a fundamental signal, and the anomaly detector's "revenue is negative" interpretation is wrong. Ignore those metrics entirely. Pre-flight and market-forces are directionally right that this is a quality name in a tailwind sector; the narrative layer's "12% premium is defensible" read is the most honest take in the file.
The contrarian case worth taking seriously: metrology capex intensity is genuinely rising with GAA/backside power/advanced packaging, but Nova is small ($881M revenue vs KLAC's ~$11B) and its growth rate is partly the 2024-2025 leading-edge capex spike, not a permanent step-up. The 2022→2023 decline (-9%) shows what a mild WFE downturn does; a real one could take revenue back to $700M and earnings to $180M, at which point 51x forward-normal earnings becomes 74x on trough and the stock re-rates to $250-300. Customer concentration (TSMC/Samsung/Intel/SK Hynix are basically the entire book) and China exposure (both as customer and competitive threat in trailing-edge metrology) are real. Insider activity is net selling — small dollar amounts but no offsetting insider buys, and the "?" on names is a data gap I don't love. The market thesis assumes metrology intensity per wafer keeps rising AND Nova keeps its share against KLAC's Onto/Candela franchises — plausible, not guaranteed.
My verdict: I dissent modestly from "fair value." At 51x earnings and 61x FCF for a cyclical equipment vendor — even a great one — you're paying for a scenario where 2026 revenue clears $1.1B and margins hold at 29%+. That's the consensus path, and I don't think you get compensated for the cyclical tail risk at this price. Fair value on normalized 2026 EPS of ~$11-12 at a defensible 30-32x multiple (premium to KLAC's ~25x for smaller/higher-growth) gets me to $340-380, not $418. I'd want $350 or below to build a position; at $418 you're underwriting perfection into a sector that has never delivered perfection through a full cycle. The narrative engine's "moderate premium, moderate durability" call is the right frame — this isn't a short (quality is real, balance sheet bulletproof, growth genuine), but it's not a buy here either. Trim if held, wait if not, revisit on any WFE-cycle scare that takes it to $320-350.
GPT Reading
What jumps out first is that this is a genuinely elite business, not a story stock pretending to be one. Revenue has gone from $416.1M in 2021 to $880.6M in 2025, more than doubling in four years despite a 2022–2023 digestion period in the broader wafer-fab equipment cycle. More important, profitability scaled with it: gross margin reached 57.4%, operating margin 28.8%, and net margin 29.4% in 2025, versus already-strong 2021 levels of roughly 57.0%, 27.0%, and 22.4%. That tells me the company is not buying growth with pricing concessions or bloated opex. Free cash flow of $217.9M on $880.6M of revenue is a 24.7% FCF margin, and operating cash flow of $245.6M exceeded capex by a wide margin. With $214.5M of cash and no debt, the balance sheet adds resilience rather than explaining the equity story. On business quality alone, this deserves a premium.
The problem is that the market already knows all of that and is paying up heavily for it. At $13.3B market cap against $880.6M of revenue, the stock is trading around 15x sales; against $259.2M of net income, about 51x earnings, consistent with the reported 52.5x P/E. For a semiconductor equipment name, that is a demanding multiple even for one with superior margins and returns on capital near 20%. To make that valuation reasonable, you need to believe that 2025’s 31% revenue growth and 41% earnings growth are not just strong but sustainably near the low end of a multi-year run. That is possible, but the annual history argues for cyclicality underneath the secular story: revenue fell from $570.7M in 2022 to $517.9M in 2023 before rebounding hard. This is not a pure software-like compounder; it is a capital equipment supplier with excellent positioning. I think the market is pricing it closer to a structurally linear grower than the historical revenue path justifies.
There is also a subtle tension between the income statement strength and the multiple being assigned to that strength. Return on equity of 19.7% and ROIC of 19.6% are excellent, but not the kind of 30%+ capital efficiency that automatically sanctifies a 50x earnings multiple. The company’s 2025 operating income was $253.5M; against a $13.3B equity value, investors are paying more than 52x operating earnings for a business exposed to customer concentration, memory/foundry capex swings, and geopolitics. The anomalous EV multiples in the feed are clearly garbage and should be ignored, but the clean data still says enough: this is a high-quality metrology franchise priced for very little operational slippage. Recent insider activity is not severe enough to be a core thesis, but the fact pattern is mostly awards paired with sales, not open-market accumulation, which is what you would rather see at a premium valuation.
The best argument against my caution is straightforward: maybe this should not be thought of as a cyclical semi-cap equipment company at all, but as a share-gaining metrology specialist whose value per wafer rises as devices get more complex. If so, the 2022–2023 wobble was just a temporary industry pause, while the long-term slope is what matters. The numbers support that case better than I’d like: 2021 to 2025 revenue CAGR above 20%, net income rising from $93.1M to $259.2M, and margins actually improving through scale. A debt-free balance sheet plus $217.9M of FCF means there is little financial fragility, and if 2026 revenue were to clear $1.05B with margins holding near 29% operating, today’s 52x P/E would compress quickly into the 30s without needing multiple expansion. In other words, if you believe metrology intensity is structurally increasing and Nova is one of a few true bottleneck vendors, the stock can look expensive and still outperform.
What would change my mind is not another narrative about AI chips or advanced packaging; it is evidence that growth is either more durable or more fragile than the current price implies. If the company can sustain 25%+ revenue growth on top of the 2025 base while keeping gross margin above 56% and FCF margin above 22%, then the premium is deserved and I would be too conservative here. Conversely, a slowdown into the mid-teens, any clear gross-margin compression below 54%, or signs that earnings growth is slipping materially below revenue growth would matter a lot because 50x earnings leaves no shelter. For me, the stock is not broken; it is just priced as if the next few years will look far better and smoother than the last few did.
Grok Reading
The numbers describe a genuine compounder, not a narrative mirage. Nova roughly doubled revenue from the 2023 trough of $517.9M to $880.6M in 2025, with net income climbing from $136.3M to $259.2M—an earnings CAGR near 38% against a 30% revenue CAGR. Gross margin held at 57%, operating margin expanded to 29%, and free cash flow of $217.9M converted almost fully from $245.6M of operating cash with only $27.7M of capex. Zero debt against $214.5M cash and a current ratio above 6 leaves the balance sheet unlevered and liquid. That profile—high-teens ROE/ROIC, sub-30% of revenue in opex drag, and FCF quality that tracks earnings—explains why the market has awarded a 52.5x P/E and roughly 15x sales on the $13.3B capitalization. The growth is real and the economics are elite for equipment.
What stands out against the quantitative models is how little cushion remains once that growth is fully priced. The valuation synthesis already marks composite fair value near $219 and a signal-adjusted $372, implying the $418 print sits about 11% above even the optimistic reconciliation. Several canonical multiples are simply broken—negative EV/EBITDA and EV/revenue, P/B and P/S near zero—so they cannot be used; the usable anchors are the 52x earnings multiple and the FCF yield of roughly 1.6%. At that yield, the market is underwriting continued 30%+ top-line expansion and further margin stability. Semi-equipment rarely delivers that without interruption; the 2022-to-2023 revenue dip from $571M to $518M is a reminder that the cycle still bites. Insider activity in mid-2026 is net selling after awards, which is not catastrophic in size but does nothing to support the idea that management sees deep undervaluation at these levels.
The bull case that would overturn a cautious stance is straightforward and already embedded in the pre-flight thesis: advanced-node and chiplet complexity raise metrology intensity per wafer enough that Nova’s installed base and mix shift sustain mid-20s growth even if overall WFE flattens. If that intensity thesis is correct, 52x on a still-growing $259M earnings base can compress gently through earnings rather than price. The rule-based archetype of high-growth profitable fits, and sector-relative margins and returns are clearly above benchmark. Yet the narrative layer itself rates durability only moderate and the premium only about 12%, which is consistent with a stock that has already captured most of the structural story.
The strongest counter-argument is that you are underweighting durability of the moat and the quality of the cash engine. A skeptic of the overvalued read would note that FCF has compounded at 43%, net margins expanded into the high 20s, and the company generates more cash than it needs to grow, so a premium multiple is the normal state rather than a temporary excess. They would also argue that comparing Nova to diversified peers at 15–20x is apples-to-oranges because optical and x-ray metrology at leading-edge nodes is less commoditized and more recurring than broad deposition or etch. That critique has force: the operating history from 2021 through 2025 shows successive re-acceleration rather than a one-cycle spike, and customer willingness to pay for yield-critical tools has historically protected leaders through softer WFE years. I weigh it seriously, but not enough to ignore that $418 already embeds the optimistic path; any deceleration toward mid-teens growth would leave the multiple exposed without a valuation floor near current levels.
Mind-changers would be clear: four consecutive quarters that sustain ≥25% revenue growth with stable or rising operating margins would justify holding the multiple and flip the stance toward fairly valued or better; conversely, a printed WFE down-cycle that drops Nova’s quarterly run-rate below a $200M pace, or evidence of share loss at the leading edge to cheaper Chinese or larger-peer metrology suites, would confirm overvaluation and push for a deeper discount toward the unadjusted $219 composite.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue has compounded from $416M (2021) to $881M (2025), a ~21% CAGR with only one down year (2023, -9% cyclical dip) that was followed by a sharp rebound. Gross margin sits in a tight 55-58% band and operating margin has expanded to 28.8% in 2025 (vs 27% in 2021), showing genuine operating leverage rather than mix noise. Net income scaled from $93M to $259M and FCF from $127M to $218M, with OCF/NI of 1.08x and accruals at -1% of assets confirming earnings are cash-backed. Beneish M of -2.3 and Altman Z of 9.6 sit deep in the safe zone. Balance sheet is a fortress: $536M net cash, zero net debt, self-funding capex. Dilution is the one blemish - diluted share count crept from 29.8M to 32.8M (2.4% CAGR) despite buybacks offsetting 89% of SBC, so per-share value is being modestly leaked. Insider tape shows small routine sells against awards, no open-market buying but no alarming distribution either. The business reads as a specialized metrology player benefiting from advanced-node and packaging complexity; the trajectory is that of a compounder, not a cyclical laggard.
Verify before trusting this (6)
- Customer concentration - what % of revenue comes from top 1-3 customers (likely TSMC, Samsung, Intel, SK Hynix)
- Segment mix between advanced-node process control vs advanced packaging metrology and services attach
- Backlog and book-to-bill trend to confirm 2025 growth is not a pull-forward
- SBC structure and whether the 2.4% dilution rate is expected to persist or normalize
- R&D as % of revenue trend to confirm technology leadership investment is being sustained
- Geographic revenue exposure, particularly China risk given export controls
The composite fair value of $219 and signal-adjusted $372 both sit below the $418 price, implying roughly -11% to -47% downside depending on weighting. The DCF ($117) and EPV floor ($45) look like runaway-conservative outputs that ignore Nova's structural growth and net-cash balance sheet, so I discount them heavily. The anchored-PE of $430 is the most credible anchor and lands essentially on today's price — meaning the market is already paying a full multiple for the quality the company-quality lens confirmed. Earnings quality is high, so no haircut is warranted, but that just validates the deserved value, it does not create a discount. What is priced in: continued fab capex growth, share gains in advanced-node metrology, and margin durability through cycles. What has to go right: no meaningful cyclical air-pocket, no Chinese share loss at trailing nodes, and continued mid-teens+ topline compounding. That is plausible but not conservative — it is the bull case as base case. There is no margin of safety at $418; a cyclical wobble or multiple compression to a more normalized semi-cap PE would take the stock meaningfully lower before the quality reasserts itself.
Verify before trusting this (4)
- Forward WFE / fab capex commentary from ASML, AMAT, LRCX for cycle direction
- Advanced-node metrology share vs KLA and any China trailing-node erosion
- Backlog and book-to-bill trend in the next 1-2 prints
- Any guidance revision that would move anchored-PE earnings base
The tape is calm and mildly risk-on (VIX 14.3, S&P near highs, regime established 10 days), and that lands hard on NVMI because beta 1.78 amplifies whatever direction the market chooses. Right now that amplification works in its favor: semicap has been a leadership pocket, and NVMI carries a moderate-intensity 'indispensable metrology chokepoint' narrative that fits the AI/leading-edge capex story the market is happy to pay up for. Momentum (30% CAGR, steady positive drift) is the tell that flows are with it, not against it.
Verify before trusting this (5)
- Any crack in leading-edge fab capex guidance from TSMC/Samsung/Intel prints
- VIX break above 18 or a decisive S&P rejection at highs - would flip beta 1.78 from asset to liability
- 10y yield pushing through 4.8-5.0% and pressuring semicap multiples
- Sell-side target revisions and any downgrades citing China metrology competition
- Rotation out of semicap into defensives as a leadership change signal
AI reaches Nova through three channels of very different sign. Demand: AI compute is the single biggest driver of leading-edge and HBM capacity, and Nova's monetized unit — measurement steps and tools per fab — expands with architectural complexity, which is why it is taking share against a flat industry. Product: optical critical-dimension metrology is an inverse problem solved by physical modeling, so cheaper and stronger ML directly improves accuracy and time-to-recipe, deepening the incumbency of Nova's model libraries rather than commoditizing them — the scarce inputs are the optics, the sensors and the fab-qualified reference data, not the compute. Threat: the same intelligence lets customers predict rather than measure, and lets Chinese and other entrants close the algorithm gap on trailing nodes faster than they could close a physics gap. Net: cheap intelligence enlarges the addressable measurement problem more than it removes the need to physically measure, and Nova owns both the hardware and increasingly the modeling software that captures it.
None surfaced.
Verify before trusting this (8)
- Leading-edge wafer starts and HBM capacity adds
- Metrology steps per node transition
- Advanced packaging inspection budgets
- Time-to-recipe improvement claims
- ML-based modeling in new platforms
- Third-party algorithm offerings on rival hardware
- High-NA-era metrology requirements
- Sensor/optics supply chain control
The world is spending more per wafer, not necessarily on more wafers. Leading-edge logic (GAA, backside power), HBM/DRAM stacking and advanced packaging all raise process complexity, and complexity is measured — every added step is a metrology and yield-control step. That is why a ~2% industry can host a ~31% metrology grower. The offsets are macro (10y at 4.63 with headwind conditions raises the cost of fab capital and can slow mature-node projects) and geopolitical (China localization removing trailing-node demand while export controls narrow the served market). Net: the secular direction of measurement intensity is a genuine, company-specific tailwind that survives a cyclical air pocket, but it does not immunize a single quarter's shipment schedule.
Prediction unavailable. valuation-synthesis has no result for NVMI — the prediction needs its fair-value anchors.